Overview
Learn about next-generation sequencing (NGS) applications in liquid biopsy for lung cancer through this 27-minute webinar presented by Dr. Anuradha Chougule, a National Cancer Institute postdoctoral fellow. Explore how NGS technology simultaneously detects multiple driver oncogenes while analyzing limited tissue sample amounts, with a focus on druggable mutations affecting over 50% of NSCLC patients. Discover the potential of circulating tumor DNA (ctDNA) dynamics as a promising liquid biopsy biomarker for monitoring treatment response, disease progression, and prognosis prediction. Gain insights into the Oncomine Lung cfTNA Research Assay's capabilities in detecting tumor-derived cell-free DNA and RNA from blood plasma samples. Healthcare professionals can earn PACE credits through Labroots' platform, valid until March 2025.
Syllabus
Clinical utility of NGS in liquid biopsy for lung cancer
Taught by
Labroots